Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MyeloMATCH Treatment Trial)

NCT06917911 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

162

Enrollment

NIH

Sponsor class

Conditions

Core Binding Factor Acute Myeloid Leukemia

Interventions

PROCEDURE: Biospecimen Collection
PROCEDURE: Bone Marrow Aspiration
PROCEDURE: Bone Marrow Biopsy
DRUG: Cytarabine
DRUG: Daunorubicin Hydrochloride
PROCEDURE: Echocardiography Test
DRUG: Gemtuzumab Ozogamicin
PROCEDURE: Multigated Acquisition Scan
DRUG: Venetoclax

Sponsor

National Cancer Institute (NCI)